Pharma BD Deal Intelligence
Roche/Genentech's $725M upfront bet on Seragon's SERD franchise failed on its own terms—both lead assets ARN-810/GDC-0810 and GDC-0927 were scrapped by 2017—but the program's next-generation successor giredestrant is now delivering positive Phase III data over a decade later, with FDA approval decisions still pending and zero revenue booked from the original deal as of mid-2026.
Roche agreed to pay $725M upfront and up to $1B in milestones for Seragon, betting next-gen oral SERDs led by ARN-810 could rewrite the standard of care in ER+…
Roche scrapped RG6046, the centerpiece of its 2014 Seragon acquisition, but kept investing in follow-on SERDs that would later become giredestrant.
FDA accepted the NDA for giredestrant in ESR1-mutated, ER+ advanced breast cancer — a regulatory milestone tracing back to the 2014 Seragon acquisition.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Roche/Genentech acquired private San Diego biotech Seragon Pharmaceuticals (spun out of Aragon/J&J) for $725M cash plus up to $1B in milestones, gaining a portfolio of oral SERDs led by ARN-810 for ER+ breast cancer. The deal seeded what later became Roche's giredestrant program.
Assessment window: 5yr post-close.
240K US cases/yr
Hormone receptor-positive (ER+/HER2-) breast cancer accounts for ~73% of all breast cancers and remains the largest molecular subtype, with the disease driven by estrogen-mediated proliferation. While early-stage prognosis is favorable, advanced ER+ disease eventually develops endocrine resistance, often via acquired ESR1 mutations.
The ER+ metastatic breast cancer landscape is anchored by AstraZeneca's Faslodex (fulvestrant, the only approved injectable SERD) layered on top of CDK4/6 inhibitors — Pfizer's Ibrance (palbociclib), Novartis's Kisqali (ribociclib), and Lilly's Verzenio (abemaciclib). The 2014 Roche/Seragon $725M upfront ($1.725B biobucks) deal was a landmark bet that next-generation ORAL SERDs could displace fulvestrant and combine more cleanly with CDK4/6i. Lead asset ARN-810/RG6046/GDC-0810 was discontinued in 2017, but the program seeded giredestrant (GDC-9545), which is now in Phase 3 (persevERA, lidERA, evERA) and received FDA NDA acceptance in February 2026 for ESR1-mutated ER+/HER2- mBC. Competing oral SERDs include AstraZeneca/Lilly's Orserdu (elacestrant, FDA-approved January 2023 for ESR1-mutated mBC) and Sanofi's amcenestrant (discontinued 2022). The deal's payoff has shifted from ARN-810 to giredestrant, reframing the acquisition as a long-tail platform purchase rather than an asset-specific bet.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Seragon Pharmaceuticals, Inc. (this deal) | 2014 | $1.7B | 53 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2014 deals · Roche Holding AG deals · Oncology deals